Details for New Drug Application (NDA): 209543
✉ Email this page to a colleague
NDA 209543 describes BOSUTINIB MONOHYDRATE, which is a drug marketed by Alembic and is included in one NDA. Additional details are available on the BOSUTINIB MONOHYDRATE profile page.
The generic ingredient in BOSUTINIB MONOHYDRATE is bosutinib monohydrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.
The generic ingredient in BOSUTINIB MONOHYDRATE is bosutinib monohydrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.
Summary for 209543
| Tradename: | BOSUTINIB MONOHYDRATE |
| Applicant: | Alembic |
| Ingredient: | bosutinib monohydrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 100MG BASE | ||||
| Approval Date: | May 23, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 500MG BASE | ||||
| Approval Date: | May 23, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
